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Background: Genetic modifiers are important clues for the identification of therapeutic targets in
neurodegenerative diseases. Huntington disease (HD) is one of the most common autosomal dominant inherited
neurodegenerative diseases. The clinical symptoms include motor abnormalities, cognitive decline and behavioral
disturbances. Symptom onset is typically between 40 and 50 years of age, but can vary by several decades in
extreme cases and this is in part determined by modifying genetic factors. The metabolic master regulator PGC-1α,
coded by the PPARGC1A gene, coordinates cellular respiration and was shown to play a role in neurodegenerative
diseases, including HD.
Methods: Using a candidate gene approach we analyzed a large European cohort (n = 1706) from the REGISTRY
study for associations between PPARGC1A genotype and age at onset (AO) in HD.
Results: We report that a coding variant (rs3736265) in PPARGC1A is associated with an earlier motor AO in men
but not women carrying the HD mutation.
Conclusions: These results further strengthen the evidence for a role of PGC-1α in HD and unexpectedly suggest a
gender effect.
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Huntington disease (HD) is an autosomal-dominantly
inherited, neurodegenerative disorder caused by the abnor-
mal expansion of a CAG repeat tract in the huntingtin
gene. The clinical picture of HD is characterized by a com-
bination of a progressive movement disorder (chorea), cog-
nitive decline and behavioral disturbances typically
presenting in mid-life. However, disease onset and symp-
toms vary widely between individual patients. The length of
the CAG repeat in the huntingtin gene and the resulting
polyglutamine tract in the huntingtin protein is the major
determinant of age at motor symptom onset, accounting
for about 70% of the variability [1]. The remaining* Correspondence: patrick.weydt@uni-ulm.de
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stated.variability is shaped by genetic and environmental factors
that remain incompletely understood [1]. Since genetic and
environmental modifiers may provide clues for the identifi-
cation of therapeutic targets in HD and possibly other neu-
rodegenerative diseases, substantial research efforts are
being invested into their discovery and characterization [2].
Genetic modifiers can be identified with two alternative
general methodologies: the hypothesis-driven candidate
gene approach and unbiased genomewide screens.
PGC-1α was identified as a candidate gene after it was
discovered that PGC-1α −/− mice develop neurodegen-
eration and that PGC-1α dependent genes are down-
regulated in human HD brains [3-7].
The transcriptional co-activator PGC-1α is a metabolic
master regulator that orchestrates the adaptation of the cell
to changing energy demands [8]. Originally described asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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tissue [9], PGC-1α is now known to participate in many
cell types in a wide range of essential and ancilliary meta-
bolic processes, such as angiogenesis, antioxidative de-
fense and autophagy. The human PPARGC1A gene was
cloned in 1999 and subsequently found to be a genetic
modifier in several metabolic diseases [10,11]. In addition
to HD, PGC-1α was also implicated as an important
modifier of other neurodegenerative diseases, including
Parkinson disease and amyotrophic lateral sclerosis (ALS)
[12,13]. The role of PGC-1α in the pathophysiology of
neurodegenerative diseases is likely to be complex and dif-
fers between disease entities [14]. A route towards resolv-
ing this complexity is the detailed characterization of the
PPARGC1A locus, its variant transcripts and SNPs that
are associated with disease onset. This strategy has re-
sulted in the identification of a novel promoter, new brain
specific PGC-1α isoforms and new variants associated
with HD age at symptom onset [15].
In HD, independent analysis of three European HD
cohorts suggested a protective effect of SNP 7665116 on
age of onset in HD [16-18]. Further SNPs, for which an
effect on AO was reported, include rs2970870,
rs2970848 and rs6821591 [15,19,20]. These SNPs all
map to non-coding portions of the gene.
As non-synonymous SNPs may be associated with
functional changes of the protein, we have previously
studied associations of rs8192678, the most frequent
SNP in the coding region (minor allele frequency ~0.35)
with HD AO, but found no associations in a smaller Ital-
ian population [16]. As the current population is much
larger and therefore increases the power to detect effects
of less common SNPs, we studied the next common
coding SNP, rs 3736265 (minor allele frequency ~0.05).
Here we report, that this SNP is significantly associated
with AO and that this association is male-specific.
Methods
We analyzed DNA samples and clinical data provided by
the European HD network REGISTRY study, one of the
largest cohorts available for this kind of study [21]; (www.
euro-hd.net). In DNA from 1706 unrelated symptomatic
HD patients (869 men/837 women), rs3736265 was typed
using a TaqMan Genotyping Assay (C_25935762_20, Ap-
plied Biosystems). Correct genotyping was verified in 10%
of the samples. Allele frequencies were estimated by gene
counting. Agreement with Hardy-Weinberg equilibrium
was ascertained using a χ2 goodness-of-fit test. Association
of rs3736265 with motor AO was ascertained in a linear
model. As we observed a skewed relationship between the
expanded CAG repeat size and age of onset as expected,
we used logarithmically transformed AO as the dependent
variable and rs3736265 (coded as 0, 1 and 2) and normal
and expanded CAG repeat sizes as well as their interactionsas independent variables (Duyao M et al. 1993, Soyal SM
et al. 2012). We observed a linear relationship between HD
CAG repeat size and log-transformed AO. Furthermore,
the residuals appeared to follow a normal distribution as
judged by the Kolmogorov-Smirnov test. The access to the
databases used in our work is publicly available. Partici-
pants gave informed written consent according to the Inter-
national Conference on Harmonisation-Good Clinical
Practice (ICH-GCP) guidelines (http://www.ich.org/LOB/
media/MEDIA482.pdf). For participants, who lacked cap-
acity to consent, study sites adhered to country-specific
guidelines for obtaining consent. Minors assented with both
parents consenting for them. Ethical approval was obtained
from the local ethics committee for each study site contrib-
uting to REGISTRY [21].
Results and discussion
The results of the genotyping are summarized in Table 1.
The distribution of genotypes associated with rs3736265
met Hardy-Weinberg (HW) expectations. The minor allele
frequency (MAF) is 0.0554. 186 of the 1706 samples
(10.1%) were heterozygous and two samples were homozy-
gous for the minor allele. In the overall population analysis
there was no significant effect in the additive model, but a
significant effect in the dominant model (p = 0.0519 and
0.0170, respectively). Gender stratification revealed that the
SNP effect was observed in the male population and both
the additive and the dominant model reached significance
in men after the Bonferroni correction (p = 0.0328 and
0.0084, respectively). The difference in AO between male
patients harboring two major alleles and a minor allele
was ~2.6 years, while in women AO was not significantly
affected.
The fact that rs3736265 is a low frequency SNP im-
plies that small differences in analysis might affect the
significance of the association. We therefore scrutinized
the robustness of the association. First, three men were
homozygous, possessing HD alleles with 54 and 37, 50
and 37 or 44 and 36 CAG repeats. Exclusion of these
subjects from the analysis showed p-values of 0.0040
and 0.0036 for rs3736265 in the additive and dominant
model, respectively. Second, differences in the relation-
ship between CAG repeat length and AO were noted be-
tween the sixteen study centers. Adjustment for these
differences did not affect the significance of the associ-
ation of rs3736265 with logarithmically transformed AO
(p-values 0.0047 and 0.0044 for additive and dominant
model, respectively). Third, according to a previous
study, the normal CAG repeat has no effect on AO [22].
We therefore omitted the normal allele and its product
with the HD allele from the analysis and found similar
p-levels (0.0037 and 0.0034). Fourth, few samples at the
end of the distribution with large repeats may dispropor-
tionally drive the results obtained. To address this
Table 1 Effect of PPARGC1A rs3736265 on AO
rs3736265 genotype P1 P2
CC CT TT
All
N 1518 186 2
HD CAG repeat size 44.7 (4.6) 44.7 (3.8) 46.0 (2.8) n.s. n.s.
non-HD CAG repeat size 18.5 (3.4) 18.5 (3.3) 19.0 (2.8) n.s. n.s
CAG-product3 828 (178) 831 (185) 870 (76) n.s. n.s.
Log AO4 1.641 (0.128) 1.627 (0.126) 1.601 (0.088) 0.0519 0.0170
AO5 43.75 42.36 39.9
Men
N 784 84 1
HD CAG repeat size 44.8 (4.5) 44.5 (.2) 44.0 (0) n.s. n.s.
non-HD CAG repeat size 18.6 (3.5) 18.8 (3.5) 21.0 (0) n.s. n.s
CAG-product3 836 (185) 840 (176) 924 (0) n.s. n.s.
Log AO4 1.655 (0.128) 1.629 (0.126) 1.638 (0) 0.0164 0.0042
AO5 45.19 42.56 43.45
Women
N 734 102 1
HD CAG repeat size 44.5 (4.7) 44.8 (4.2) 48.0 (0) n.s. n.s.
non-HD CAG repeat size 18.4 (3.4) 18.3 (3.2) 17.0 (0) n.s. n.s.
CAG-product3 818 (170) 823 (192) 816 n.s. n.s.
Log AO4 1.626 (0.128) 1.622 (0.127) 1.568 (0) 0.6732 0.5705
AO5 42.27 41.88 36.98
Data are means (SD); P1, additive model; P2, dominant model; ANOVA; 3product of the CAG sizes in the two alleles 4adjusted for HD CAG and non-HD CAG sizes
and their products. 5ANOVA was used and the p-values refer to the log-transformed age-at-onset. The age-at-onset is only shown to give an estimate of the ef-
fects that is easier to interpret. All genotype distributions are in HW equilibrium, MAF in entire population 0.0554.
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size > 55 and observed similar p-values as in the entire
male cohort (0.0044 and 0.0040). Additional exclusion of
12 patients with HD-CAG size <40 resulted in p-values
of 0.0075 and 0.0070. We also addressed the issue of
modifying effects in women with <55 CAG repeats and
found no modifying effect of rs3736265 (P-values 0.882
and 0.843 for the additive and dominant models). Fi-
nally, the collection of subjects from different European
regions and in different centers is likely to result in a re-
duced signal-to-noise ratio compared to smaller single-
region or single-center studies. Hence, the association
observed is robust and fulfills the expectations of linear
models as linear relationships between variable and a
normal distribution of residuals were observed.
The PPARGC1A genomic locus is of potential import-
ance for understanding the mechanisms of PGC-1α ac-
tion in HD pathogenesis. We thus examined this locus
in more detail and demonstrate that a SNP in the coding
region of PPARGC1A has a significant effect on age of
onset in HD.
SNP rs3736265 is located in exon 9 of PPARGC1A,
hence contained in many different tissue specific PGC-1α isoforms reported to date, i.e. PGC-1α1-4 and PGC-
1αB1-5 [15,23]. It results in a Thr612Met amino acid ex-
change. Hence, a polar, aliphatic amino acid (threonine)
is substituted by a sulphur-containing hydrophobic, ali-
phatic amino acid (methionine). The amino acid stretch
comprising the more common threonine is predicted to
have a random coil or extended strand structure. The
substitution by methionine is likely to result in an α-
helical structure of five amino acids [24]. Co-activation
of PPARγ on the acyl-CoA-binding promoter did not
differ between PGC-1α proteins harboring threonine or
methionine at amino acid residue 612 [25]. However, a
recent study reported significant associations of
rs3736265 with neovascularization in age-related macu-
lar degeneration (AMD) as well as interactions with the
AMD-associated genes encoding complement factor B
and VEGFA [26].
Surprisingly, the described SNP effect is clearly male-
specific, while HD - unlike other neurodegenerative dis-
eases - does not show a gender bias. This is reflected in
our study population with a balanced male to female ra-
tio (1.04). Some gender differences in HD are emerging:
In the REGISTRY population women tend to have
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disease progression than matched male controls [27].
This however did not translate into differences in age at
symptom onset. Mochel et al. found a lower body mass
index (BMI) and lean body-mass despite a higher caloric
intake in men but not in women [28]. Similarly, a trans-
genic rat model of HD displayed a marked male-specific
gender-bias of symptoms [29]. This study includes a
gene-expression profiling study on human HD striata
showing only 42 genes to be differentially regulated be-
tween men vs. women with HD, compared to 343 genes
differentially regulated between male vs. female controls.
A possible explanation for the weakness of this signal is
that the 1.5 fold-change cut-off in the analysis is too
strict to allow for PGC-1α connected changes to become
evident [5]. Thus, a net-work based analysis may have
been superior to a bioinformatics approach that looks at
each transcript in isolation. Finally, sex-specific influ-
ences of genetic modifiers in HD have been reported for
apolipoprotein E [30] and for the NR2A and NR2B re-
ceptor genes [31], but these results were not confirmed
in other studies [32,33]. An important difference be-
tween these studies and our present work is that our
HD cohort is larger by an order of magnitude (n = 138
and n = 250 vs. n = 1706, respectively). Nevertheless,
the association we report here awaits independent
confirmation.Conclusions
In summary our result further strengthens the accumulat-
ing evidence for a role of the PGC-1α-pathway in HD in
particular and neurodegeneration in general and underlines
that gender differences in neurodegenerative diseases might
be due to differences at the molecular level [34].Competing interests
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